Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Benny Sorensen
- Full Time Employees
- 59
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 101 Main Street Cambridge MA United States of America 02142
- IPO Date
- May 1, 2026
- CIK
- 0002114044
- Website
- hemab.com
- Similar Companies
- Business
- Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing prophylactic therapies for bleeding and thrombotic disorders to improve patient outcomes and quality of life. The company researches and develops next-generation coagulation-targeted biologics with the aim of providing durable, preventive treatments across a spectrum of underserved conditions. Main products and services: sutacimig (HMB-001), a bispecific antibody in clinical development for prophylaxis of Glanzmann thrombasthenia and Factor VII deficiency; HMB-002, a monovalent antibody in development for prophylaxis of Von Willebrand Disease; pipeline expansion targets additional novel coagulation-focused therapies designed to address high unmet-need bleeding and thrombotic disorders; clinical trial design, biomarker and natural history study collaborations to support regulatory submissions; manufacturing process development and scalable production for advanced biologics; partnership and licensing opportunities to commercialize prophylactic coagulation therapies globally. Latest major company changes: completes Series C financing of $157 million to expand pipeline and support advancement of additional candidates into clinical development, including anticipated HMB-003 in 2026; pursues expansion of therapeutic portfolio through strategic partnerships and potential acquisitions to build a comprehensive coagulation franchise; progresses initial public offering activities in 2026 to broaden equity base and support clinical programs; announces ongoing clinical and regulatory milestones across its lead programs and future candidates; broadening geographic reach through collaborations and potential international trial sites. Additional context: operates in the biotechnology and pharmaceutical sectors with a focus on coagulation disorders and underserved bleeding and thrombotic diseases; targets both patient populations with Glanzmann thromboassenemia, Factor VII deficiency, and Von Willebrand Disease, among others; primarily operates in the United States and Europe with prospective global development and commercialization plans; founded in 2020 and headquartered in Copenhagen, Denmark, with scientific and clinical operations extending to U.S. sites for trials and regulatory interactions; maintains relationships with researchers, contract research organizations, and potential strategic partners to support development, testing, and commercialization of its therapies.
Company News
Hemab Therapeutics (NASDAQ:COAG) Shares Gap Down – Here’s What Happened
Hemab Therapeutics (NASDAQ:COAG) Sees Strong Trading Volume – Should You Buy?
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives Consensus Rating of “Moderate Buy” from Analysts
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding
Hemab Therapeutics (NASDAQ:COAG) Shares Up 5.5% – Should You Buy?
Hemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical Catalysts
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
Hemab Advances Bleeding Disorder Pipeline
Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress
Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans
Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
U.S. IPO Weekly Recap: Biotech, Early-Stage Mining, And Bill Ackman Close Out The April IPO Market
Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering